Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Netflix

Shopify

Tanger Factory Outlet Centers

Veeva Systems

High-octane growth got crushed, with Veeva Systems, Shopify and others falling. Here are our top stock trades, including NFLX, JNJ and SKT.

5 Top Stock Trades for Tuesday (July 30)

GlaxoSmithKline

Thermo Fisher Scientific

It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.

Three Healthcare Stocks With Rising Expectations.

JNJ stock is in sell-off mode, but investors shouldn't  "buy the dip" until political noise fades and/or the stock gets cheaper. 
The post Why Johnson & Johnson Stock Isn’t a Buy… Yet appeared first on InvestorPlace.

Why Johnson & Johnson Stock Isn’t a Buy… Yet

Abbott Labs

Amgen

AstraZeneca

Eli Lilly

Merck

Novartis

Pfizer

Roche Holding AG

The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

10 Biggest Cancer-Fighting Stocks

Baxter

Becton, Dickinson and Co.

Boston Scientific

Edwards Lifesciences

Illumina

Intuitive Surgical

Medtronic

Stryker

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

Eye issues have sparked the company to take this light mask off the market.

Neutrogena recalls its light therapy acne mask

Johnson & Johnson's dividend yield is 80 basis points higher than the 10-year.

Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World

JNJ has a history of delivering decent returns for shareholders. But if lawsuits make you nervous, I’d avoid JNJ stock for now.

Is Johnson & Johnson Stock Losing Its Shine?

After its last earnings report, Johnson & Johnson (NYSE:JNJ) looks like a good target for a cheap ratio call debit spread.
The post Johnson & Johnson Could Turn Around After its Strong Earnings appeared first on InvestorPlace.

Johnson & Johnson Could Turn Around After its Strong Earnings

AvalonBay Communities

NextEra Energy

These income stocks look incredibly secure for a long time to come.

3 of the Most Rock-Solid Dividend Stocks in the World

Boeing

Coca-Cola

McDonald's

UnitedHealth Group

What goes up must come down sooner or later. After a fantastic run, the Dow Jones is vulnerable to some selling, and these five stocks could get hit.

5 Dow Jones Stocks to Sell Before the Market Slumps

Apple

Amazon

Alphabet

JPMorgan Chase & Co

Microsoft

Visa

Exxon Mobil

These top-quality stocks lead their industries, and they've been good to investors over the long run.

The 10 Biggest Blue Chip Stocks

A US judge presiding over multidistrict litigation alleging J&J's talc baby powder causes ovarian cancer starts hearing from experts Monday.

Johnson & Johnson faces a crucial hearing Monday over thousands of talc baby powder lawsuits

The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.

Judge denies J&J's request to transfer 2,400 talc lawsuits to federal court

Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.

3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.

5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report

Johnson & Johnson (NYSE: JNJ) shares are down 2% since the company reported a second-quarter earnings beat on Tuesday morning.

After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk

Johnson & Johnson (JNJ) Q2 2019 Results - Earnings Call Transcript

One company that has been a champion for investors has been Johnson & Johnson (NYSE: JNJ).

Why J&J Shareholders May Have to Ignore Earnings Looking Ahead

Roku

Uber

Wells Fargo

Blue Apron

Blue Apron, Wells Fargo, Johnson & Johnson, Roku and Uber were our top stock trades to watch going into Wednesday's trading session. 
The post 5 Top Stock Trades for Wednesday: JNJ, WFC, UBER, APRN, ROKU appeared first on InvestorPlace.

News for Johnson & Johnson Stock (JNJ)